[go: up one dir, main page]

PL1945647T3 - Processes for preparation of maytansinol - Google Patents

Processes for preparation of maytansinol

Info

Publication number
PL1945647T3
PL1945647T3 PL06844315T PL06844315T PL1945647T3 PL 1945647 T3 PL1945647 T3 PL 1945647T3 PL 06844315 T PL06844315 T PL 06844315T PL 06844315 T PL06844315 T PL 06844315T PL 1945647 T3 PL1945647 T3 PL 1945647T3
Authority
PL
Poland
Prior art keywords
maytansinol
preparation
processes
bridged
scaleable
Prior art date
Application number
PL06844315T
Other languages
Polish (pl)
Inventor
Ravi V J Chari
Wayne C Widdison
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of PL1945647T3 publication Critical patent/PL1945647T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention describes the preparation of maytansinol by methods that minimize processing steps, and reduce solvent volumes, making the process more efficient, and scaleable. This process comprises a step of converting bridged acetals of maytansinol to maytansinol. The simplified processing also aids in lowering the potential for human exposure to chemicals. Also provided is an isolated C3 to C9 bridged acetal of maytansinol.
PL06844315T 2005-11-08 2006-11-08 Processes for preparation of maytansinol PL1945647T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73433005P 2005-11-08 2005-11-08
PCT/US2006/043718 WO2007056550A2 (en) 2005-11-08 2006-11-08 Processes for preparation of maytansinol
EP06844315A EP1945647B9 (en) 2005-11-08 2006-11-08 Processes for preparation of maytansinol

Publications (1)

Publication Number Publication Date
PL1945647T3 true PL1945647T3 (en) 2012-04-30

Family

ID=38024003

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06844315T PL1945647T3 (en) 2005-11-08 2006-11-08 Processes for preparation of maytansinol

Country Status (10)

Country Link
US (1) US7411063B2 (en)
EP (1) EP1945647B9 (en)
JP (1) JP5117390B2 (en)
AT (1) ATE540956T1 (en)
AU (1) AU2006311485B2 (en)
CA (1) CA2625867C (en)
DK (1) DK1945647T3 (en)
ES (1) ES2380687T3 (en)
PL (1) PL1945647T3 (en)
WO (1) WO2007056550A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP5276017B2 (en) 2007-01-25 2013-08-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Use of anti-EGFR antibodies in the treatment of EGFR mutant mediated diseases
US9023356B2 (en) 2007-03-15 2015-05-05 Ludwig Institute For Cancer Research Ltd Treatment method using EGFR antibodies and SRC inhibitors and related formulations
US9283276B2 (en) 2007-08-14 2016-03-15 Ludwig Institute For Cancer Research Ltd. Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof
FR2949469A1 (en) * 2009-08-25 2011-03-04 Sanofi Aventis ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
TWI541022B (en) 2013-12-18 2016-07-11 應克隆公司 Compounds to fibroblast growth factor receptor-3 (fgfr3) and methods of treatment
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
TW201711702A (en) 2015-06-04 2017-04-01 應克隆公司 Therapies utilizing compounds to fibroblast growth factor receptor-3 (FGFR3)
EP3319936A4 (en) 2015-07-12 2019-02-06 Suzhou M-conj Biotech Co., Ltd. PLACES OF CONDUCT FOR THE CONJUGATION OF CELL BINDING MOLECULES
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR102459469B1 (en) 2016-11-14 2022-10-26 항저우 디에이씨 바이오테크 씨오, 엘티디 Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
CA3047115A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
ES2949511T3 (en) * 2019-03-01 2023-09-29 Celgene Corp Preparation of maytansinol
JP7568644B2 (en) 2019-04-18 2024-10-16 インデナ エッセ ピ ア Diastereoselective methods for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof
TW202116778A (en) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 Peptide conjugates of cytotoxins as therapeutics
BR112022000297A2 (en) 2019-07-10 2022-03-15 Cybrexa 3 Inc Peptide conjugates of microtubule targeting agents as therapeutics
JP7772363B2 (en) 2019-11-29 2025-11-18 日本マイクロバイオファーマ株式会社 Enzymatic production of maytansinol
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5566586A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1507781A4 (en) * 2002-05-13 2006-03-15 Smithkline Beecham Corp Process for preparing maytansinol

Also Published As

Publication number Publication date
EP1945647A2 (en) 2008-07-23
US20070112188A1 (en) 2007-05-17
ES2380687T3 (en) 2012-05-17
WO2007056550A2 (en) 2007-05-18
CA2625867A1 (en) 2007-05-18
CA2625867C (en) 2014-12-23
JP5117390B2 (en) 2013-01-16
AU2006311485A1 (en) 2007-05-18
EP1945647A4 (en) 2010-10-20
US7411063B2 (en) 2008-08-12
ATE540956T1 (en) 2012-01-15
EP1945647B9 (en) 2012-11-14
JP2009514978A (en) 2009-04-09
DK1945647T3 (en) 2012-05-07
AU2006311485B2 (en) 2012-09-27
EP1945647B1 (en) 2012-01-11
WO2007056550A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
PL1945647T3 (en) Processes for preparation of maytansinol
WO2007024958A3 (en) Noise mitigating microphone system and method
EP1580730A3 (en) Isolating speech signals utilizing neural networks
ATE427965T1 (en) ANTIBODIES AGAINST 25-HYDROXYVITAMIN D
WO2005025496A3 (en) Aliphatic pyrazinoylguanidine sodium channel blockers
EA201300253A1 (en) METHOD OF OBTAINING EPOXIDE
WO2005016879A3 (en) Cyclic pyrazinoylguanidine sodium channel blockers
WO2006018220A8 (en) Method for the production of dihydropteridinones
TW200737762A (en) Method of generating code sequence and method of transmitting signal using the same
PL1633697T3 (en) Method for the production of substituted 3-aryl-butyl amine compounds
WO2003013435A3 (en) N-acetyl-d-glucosamine and process for producing n-acetyl-d-glucosamine
UA89390C2 (en) Method for producing annelated piperazin-2-one derivatives and intermediates of said method
AU2007263813A8 (en) Method for producing aqueous polymer dispersion
AU2003262026A1 (en) Method of producing structural body that functions as seat, backrest, partition, etc., and structural body produced by the method
NO20082365L (en) New Method for Preparation of 5-Amino-3H-Thiazolo [4,5-D] Pyrimidin-2-One
EA200501829A1 (en) METHOD OF OBTAINING NEPEPTIDE SUBSTITUTED SPIROBENZOAZEPIN DERIVATIVES
MX2007004137A (en) Lightweight structural panel and method for making same.
SE0300765D0 (en) Process for manufacture of an allyl ether
WO2007026373A3 (en) Process for preparing rivastigmine
AP2277A (en) Process for production of 1,2,2,2-tertafluoro ethyl difluoro methyl ether.
MX2007005833A (en) Process for cleaning a filtration membrane.
ITMI20052430A1 (en) NONE
WO2004096828A3 (en) Novel method and intermediates for the preparation of 19-nor-steroid compounds
MX2010003838A (en) Method of preparing (6r)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydrop yran-2-one, and intermediate used in the method.
TW200710821A (en) Method for communication and communication device